Investment Rating - The report maintains a positive investment rating for Nextracker, categorizing it as a top recommended stock within the global renewable energy coverage of Haitong Securities [1]. Core Insights - Nextracker's Q1 2026 performance exceeded market expectations, with a significant upward revision of its fiscal year 2026 EBITDA guidance and a record backlog of orders, indicating strong solar demand and stable pricing [1][2]. - The company reported a net revenue of $864 million for Q1 2026, slightly above the market consensus of $845 million, and an adjusted EBITDA of $215 million, surpassing the expected $190 million [3][5]. - Nextracker's gross margin remained robust at 32.6%, with adjusted net income reaching $176 million, significantly exceeding market expectations [3][5]. Summary by Sections Financial Performance - For fiscal year 2026, Nextracker raised its revenue guidance from $3.2 billion to $3.245 billion, with EBITDA guidance adjusted from $775 million to a range of $750 million to $810 million [2]. - The net profit forecast was increased from $445-503 million to $496-543 million, while the gross margin is expected to remain in the "low 30%" range [2]. Order Backlog and Market Demand - As of the end of Q1 2026, Nextracker's order backlog exceeded $4.75 billion, marking the 15th consecutive quarter of growth, with a backlog-to-shipment ratio maintained above 1 [3]. - The company anticipates that 80% to 90% of the backlog will be delivered over the next eight quarters, reflecting strong demand in the U.S. market [3]. Strategic Acquisitions - Nextracker announced three completed acquisitions in advanced robotics and artificial intelligence, with a total investment exceeding $40 million, aimed at enhancing operational efficiency and reducing maintenance costs [4].

东南亚必需消费 & 可选消费 Southeast Asia Staples & Discretionary 研究报告 Research Report 30 Jul 2025 东南亚消费行业 6 月跟踪报告：印尼消费持续悲观，消费板块估值多数上行 Indonesia's consumer sentiment stays weak, but consumer sectors PE ratio are rising in ASEAN [Table_yemei1] 观点聚焦 Investment Focus [Table_Info] 市盈率 P/E 股票名称 评级 目标价 PE(2025E) PE(2026E) 资料来源： Factset, HTI Related Reports 东南亚消费行业 5 月跟踪报告：多数地区商品价格走低 Most Regions Saw Falling Commodity Prices (1 Jul 2025) 中国必需消费品 6 月价格报告：白酒价格普跌，软饮料调味品及啤酒上 涨 Prices of Wind Generally Fell, While the Prices of So ...

Investment Rating - The report assigns a rating of "Outperform" for Chart Industries, indicating an expected total return over the next 12-18 months that exceeds the relevant market benchmark by more than 10% [12]. Core Insights - Baker Hughes has proposed to acquire Chart Industries for $210 per share, totaling an enterprise value of $13.6 billion, and has terminated its merger agreement with Flowserve [2][3]. - Chart Industries reported adjusted net income of $76 million for Q2 2025, which was below market expectations of $108 million, with revenues of $1.082 billion, also falling short of the $1.103 billion consensus [2][5]. - The company has a record backlog of $5.536 billion, up from $5.14 billion in Q1 2025 and $4.85 billion in Q4 2024, with total orders for the quarter amounting to $1.5 billion [3]. Summary by Sections Financial Performance - Adjusted EBITDA for Q2 2025 was $245 million, below the expected $267 million, with a gross profit margin of 34% consistent with previous quarters [5]. - Free cash flow improved to $124 million compared to negative $80 million in Q1 2025 and $261 million in Q4 2024 [2][3]. Guidance and Outlook - The company has withdrawn its FY2025 guidance due to the proposed merger with Baker Hughes, which previously projected revenues of $4.65 billion to $4.85 billion and adjusted EBITDA of $1.175 billion to $1.225 billion [3]. - The net leverage ratio decreased to 2.85 times, down from 2.91 times in Q1 2025, with a target leverage ratio of 2.0 to 2.5 times [3].

Investment Rating - The report does not explicitly state an investment rating for CSPC Pharmaceutical Group Core Insights - CSPC Pharmaceutical Group has entered into an exclusive licensing agreement with Madrigal Pharmaceuticals for the global development, production, and commercialization of its oral GLP-1 receptor agonist, SYH2086, with a total deal value exceeding USD2 billion [6][8] - The agreement includes an upfront payment of USD120 million, potential milestone payments of up to USD1.955 billion, and royalties based on annual net sales of SYH2086 [6][8] - The partnership with Madrigal, a leading biotech in the metabolic disease space, is seen as a strong validation of CSPC's oral GLP-1RA and is expected to accelerate clinical development in the U.S. [8][9] - This deal is considered an additional upside beyond previously guided licensing deals, highlighting the value of CSPC's small-molecule platform [9] - CSPC's AI-powered small-molecule platform has also licensed multiple assets to AstraZeneca, with a total deal value reaching USD5.3 billion [10] Summary by Sections Licensing Agreement - CSPC has granted Madrigal exclusive rights to develop, manufacture, and commercialize SYH2086 globally while retaining rights for other oral GLP-1 products in China [6][8] - The total potential revenue from this agreement could reach USD2.075 billion, including upfront and milestone payments [6][8] Clinical Development - SYH2086 is currently in the preclinical stage, and the competitive landscape in the metabolic disease field is noted to be highly challenging [7][8] - CSPC's EGFR ADC has shown superior efficacy in Phase I clinical trials compared to conventional ADC drugs, with lower rates of hematologic toxicity [11] - CSPC's siRNA platform has advanced three candidates into clinical stages, indicating potential for future collaborations [12] Market Potential - The partnership with Madrigal opens up potential markets in obesity, diabetes, and MASH, enhancing the growth prospects for CSPC [8][9] - The report expresses optimism regarding future out-licensing opportunities for other products in CSPC's pipeline, which could act as catalysts for stock price growth [9]

Group 1 - The Politburo meeting on July 30 acknowledged the positive economic momentum in the first half of the year while emphasizing the need for bottom-line thinking and proactive fiscal and monetary policies [1][8] - Key areas for risk mitigation identified include real estate, local government debt, and capital markets, with a focus on enhancing domestic demand and effective investment [1][3][9] - The meeting highlighted the importance of service consumption and proposed measures to stimulate private investment and expand effective investment in the context of a weak real estate sector [10][11] Group 2 - The upcoming Fourth Plenary Session in October will directly address the formulation of the 15th Five-Year Plan, reflecting the urgency of planning in the current international environment [4][11] - The meeting's content was largely in line with expectations, with limited incremental policies introduced, leading to a muted market reaction [12]

Investment Rating - The report indicates a positive outlook for L'Oreal with an outperform rating, expecting a relative return exceeding the benchmark index over the next 12-18 months [17]. Core Insights - L'Oreal's revenue for the first half of 2025 (25H1) increased by 1.59% year-over-year, slightly surpassing Bloomberg's consensus forecast of 1.56% [4][9]. - The company's gross profit rose by 1.4%, also above the expected 1.2%, but the gross margin decreased to 74.7%, down 0.1 percentage points year-over-year, which was below the forecast of 75.1% [4][9]. - Operating profit grew by 3.1%, significantly higher than the anticipated 0.5% increase, while net profit attributable to common shareholders fell by 7.9%, contrasting with the expected growth of 1.8% [4][9]. Revenue Breakdown - Revenue by division showed varied performance: - Professional Products: +4.9% YoY, exceeding the forecast of +1.4% [4][5]. - Consumer Products: +1.1% YoY, above the forecast of +0.6% [4][5]. - Luxe: +1.0% YoY, below the forecast of +2.1% [4][5]. - Dermatological Beauty: +1.7% YoY, slightly below the forecast of +1.8% [4][5]. - Revenue by geographic zone also varied: - Europe: +3.4% YoY, below the forecast of +4.5% [4][5]. - North America: +0.4% YoY, exceeding the forecast of -1.0% [4][5]. - North Asia: -1.5% YoY, below the forecast of -0.7% [4][5]. - SAPMENA-SSA: +9.2% YoY, above the forecast of +7.6% [4][5]. - Latin America: -1.0% YoY, exceeding the forecast of -3.2% [4][5]. Profitability Metrics - The gross margin decreased to 74.7%, which is a slight decline from the previous year and lower than the expected margin [4][5]. - The operating profit of €4,740 million reflects a strong performance compared to expectations, while the net profit attributable to common shareholders of €3,368 million indicates a significant decline [4][5].

Investment Rating - The report initiates coverage on 3S BIO with an "OUTPERFORM" rating and a target price of HK$45.50, indicating a positive outlook for the company's stock performance [1][2][7]. Core Insights - The company's core business is robust, with innovative products expected to drive future growth. Key products include TPO, EPO, and the leading hair loss treatment brand Mandi, which dominate their respective markets [2][9]. - The company has a strong pipeline with over 30 projects in development, including four innovative drugs currently undergoing NDA approval, which are anticipated to contribute significantly to revenue growth [2][12]. - The partnership with Pfizer for the PD-1×VEGF dual antibody SSGJ-707 is expected to reshape the global valuation landscape, with peak global sales projected to reach between US$11.3 billion and US$13.4 billion [3][6][31]. Summary by Sections Business Overview - 3S BIO has established itself as a leading biopharmaceutical company in China, focusing on nephrology, hematology, oncology, and other therapeutic areas. The company has shown steady revenue growth from RMB 55.9 billion in 2020 to an estimated RMB 91.1 billion in 2024 [9][12]. - The company’s core products, including TPO and EPO, maintain leading market shares of 67% and 42% respectively, ensuring a solid cash flow foundation [2][11]. Product Pipeline - The innovative pipeline includes promising candidates such as SSS06 (long-acting erythropoietin) and IL-17A monoclonal antibody, with peak sales potential estimated at RMB 7-10 billion [2][12]. - The company has also introduced new products in the consumer healthcare sector, targeting the growing market for hair loss treatments, with Mandi achieving sales of RMB 1.34 billion in 2024 [15]. Strategic Partnerships - The collaboration with Pfizer for SSGJ-707, a PD-1×VEGF dual antibody, is a significant milestone, with Pfizer paying US$1.25 billion upfront and potential milestone payments of US$4.8 billion, highlighting the product's anticipated market potential [31][33]. - The dual antibody is positioned to capture a substantial share of the oncology market, projected to exceed US$200 billion, as it demonstrates superior efficacy compared to existing PD-1 monoclonal antibodies [18][22]. Financial Projections - Revenue projections for 2025-2027 are estimated at RMB 19.18 billion, RMB 11.90 billion, and RMB 14.05 billion respectively, with net profits expected to reach RMB 9.36 billion, RMB 2.73 billion, and RMB 3.33 billion [7][9]. - The report employs a discounted cash flow (DCF) model with a WACC of 10% and a perpetual growth rate of 3.5%, supporting the target price of HK$45.50 per share [7].

Investment Rating - The report provides a positive outlook for Cadence, indicating an "Outperform" rating based on its strong financial performance and growth prospects [2][12]. Core Insights - Cadence reported a total revenue of $1.275 billion for Q2 2025, representing a 20% year-on-year increase, and Non-GAAP earnings per share of $1.65, up 29% year-on-year, exceeding market expectations [2][8]. - The growth was primarily driven by strong demand for AI-driven products and comprehensive growth across all business lines, including EDA, IP, and system design and analysis [2][12]. - The company has raised its full-year revenue guidance to a range of $5.21 billion to $5.27 billion, reflecting a year-on-year increase of 13% [12]. Summary by Sections Financial Performance - Cadence's Q2 2025 revenue was $1.275 billion, exceeding market expectations of $1.25 billion, with a Non-GAAP operating margin of 42.8%, up from 40.1% the previous year [2][9]. - The GAAP operating margin was reported at 19.0%, down from 27.7% due to a one-time charge related to a settlement [2][9]. Business Segments - The core EDA business grew by 16%, driven by the adoption of advanced process nodes, with over 50% of designs using Cadence Cerebrus [3][10]. - The IP business saw over 25% growth, fueled by AI and HPC infrastructure demands, while the system design and analysis business grew by 35% [3][10]. Product Innovation and Partnerships - Cadence launched the Cerebrus AI Studio, an AI-driven SoC design platform, and the Millennium M2000 AI supercomputer, which offers significant performance improvements [4][11]. - Strategic partnerships were expanded with industry leaders like SK hynix, ADI, and Samsung Foundry, enhancing collaboration in EDA software and advanced technologies [4][11]. Future Outlook - The company expects Q3 2025 revenue between $1.305 billion and $1.335 billion, with Non-GAAP earnings per share projected at $1.75 to $1.81 [12]. - Cadence plans to utilize at least 50% of its free cash flow for stock repurchases, indicating confidence in its financial health and growth trajectory [12].

"反内卷"下的涨价 [Table_Authors] 李林芷(分析师) 国内高频指标跟踪（2025 年第 29 期） 本报告导读： 消费端服务消费热度延续，投资端基建蓄力改善，生产稳中有升，工业品在 "反内 卷" 下涨价明显。 投资要点： lilinzhi2@gtht.com 登记编号 S0880525040087 宏 观 研 究 宏 观 周 报 证 券 研 究 报 告 请务必阅读正文之后的免责条款部分 宏观研究 /[Table_Date] 2025.07.27 021-23185646 梁中华(分析师) 021-23219820 liangzhonghua@gtht.com 登记编号 S0880525040019 [Table_Report] 相关报告 美国：居民消费仍具韧性 2025.07.20 生产改善，消费分化 2025.07.20 生产改善、消费平稳 2025.07.13 特朗普关税博弈再起，全球资产短期扰动 2025.07.13 外需平淡、内需分化 2025.07.06 2025-07-30 [Table_Summary] 上周高频数据显示，消费方面，商品消费仍需提振，服务消费中居 民出行、观影热度 ...

Profit Trends - In June, the decline in industrial enterprise profits narrowed, with a year-on-year decrease of -4.3%, an improvement of 4.8 percentage points from May's decline[3] - Cumulative profit growth for industrial enterprises from January to June was -1.8%, lower than the -1.1% recorded from January to May[3] Profit Margins and Industry Performance - The profit margin for June was 6.0%, showing a slight recovery from May, while the cumulative profit margin was 5.2%[6] - The automotive industry experienced the most significant profit recovery, benefiting from lower raw material prices and policy support[7] Demand and Inventory Dynamics - Industrial product inventory growth was 3.1% from January to June, indicating a passive destocking phase for enterprises[13] - Revenue growth for industrial enterprises in June was 1.6%, reflecting a slight recovery compared to the previous month[13] Future Outlook - Upcoming policies, including the "old-for-new" subsidy program, are expected to stimulate consumption and investment, potentially improving enterprise profits[17] - The "anti-involution" actions in various industries may help restore profit margins by reducing price competition[17] Risks - Uncertainties in trade relations and the effectiveness of policy measures such as "anti-involution" and "old-for-new" initiatives pose risks to profit recovery[18]